Detalles de la búsqueda
1.
Empagliflozin after Acute Myocardial Infarction.
N Engl J Med;
390(16): 1455-1466, 2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38587237
2.
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial.
Circulation;
2024 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38581389
3.
Antithrombotic Usage, Including Three-Year Outcomes With Dabigatran and Vitamin K Antagonists for Atrial Fibrillation, in Eastern Europe: A Descriptive Analysis From Phase 3 of the GLORIA-AF Registry.
Am J Ther;
31(1): e1-e12, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38231576
4.
Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
J Thromb Thrombolysis;
52(4): 1195-1206, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33929686
5.
Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study.
Eur J Epidemiol;
34(3): 247-258, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30353266
6.
Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology.
Cardiovasc Diabetol;
14: 133, 2015 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26427624
7.
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.
J Am Coll Cardiol;
2024 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38588929
8.
Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.
Eur Heart J;
33(22): 2865-72, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22843446
9.
NGAL as Biomarker of Clinical and Subclinical Damage of Kidney Function after Coronary Angiography.
Diagnostics (Basel);
13(6)2023 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36980488
10.
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome.
Can J Cardiol;
39(10): 1315-1324, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37116789
11.
Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model.
Eur J Prev Cardiol;
29(2): 328-339, 2022 03 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33623999
12.
Potential for optimizing management of obesity in the secondary prevention of coronary heart disease.
Eur Heart J Qual Care Clin Outcomes;
8(5): 568-576, 2022 08 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34315174
13.
Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries.
Eur J Prev Cardiol;
28(4): 370-379, 2021 05 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33966079
14.
Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study).
Open Heart;
7(1): e001202, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32257246
15.
Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURoObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry.
J Hypertens;
37(10): 2015-2023, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31246889
16.
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.
Circ Cardiovasc Qual Outcomes;
12(11): e005858, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31707826
17.
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry.
Eur J Prev Cardiol;
26(8): 824-835, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30739508
18.
Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey.
Int J Cardiol;
272: 20-25, 2018 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30172478
19.
Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS).
J Atheroscler Thromb;
23(5): 567-87, 2016 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26632163
20.
Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys.
Eur J Prev Cardiol;
23(15): 1618-27, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27084894